Data Composite

Drug Recalls

Recent drug recall reports from the FDA (US) and Health Canada, newest first. Each entry links to the full record -- product description, reason for recall, and severity classification -- refreshed daily.

SUN PHARMACEUTICAL INDUSTRIES INC

US Class II Ongoing · initiated 2025-10-28

Failed Dissolution Specifications: An out of specification results observed in dissolution test during analysis at 12-month long term stability station (25¿C, 6…

Agebox

US Class II Ongoing · initiated 2025-10-28

Marketed Without an Approved NDA/ANDA: presence of undeclared ibutamoren

Agebox

US Class II Ongoing · initiated 2025-10-28

Marketed Without an Approved NDA/ANDA: presence of undeclared ibutamoren

Otsuka ICU Medical LLC

US Class II Ongoing · initiated 2025-10-27

Lack of Assurance of Sterility: Potential for flexible container leaks.

JAMP SERTRALINE 50mg

Canada Type III Ongoing · initiated 2025-10-27

Product safety. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health con…

Cipla USA, Inc.

US Class II Ongoing · initiated 2025-10-24

Failed stability specifications: Out of specification for hardness test

Cipla USA, Inc.

US Class II Ongoing · initiated 2025-10-24

Failed stability specifications: Out of specification for hardness test

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-10-23

Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules.

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-10-22

cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acc…

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-10-22

cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acc…

Zydus Pharmaceuticals (USA) Inc

US Class II Ongoing · initiated 2025-10-22

cGMP deviations: an observed Out of Specification of Nitrosamine Drug Substance-Related Impurities (NDSRIs), N-Nitroso Desmethyl-Clomipramine, above the FDA acc…

Bristol-Myers Squibb Company

US Class II Ongoing · initiated 2025-10-21

Lack of Assurance of Sterility.

Kenvue Brands LLC

US Class II Ongoing · initiated 2025-10-21

Defective Container

Golden State Medical Supply Inc.

US Class II Ongoing · initiated 2025-10-20

Failed Dissolution Specifications

Imprimis NJOF, LLC

US Class III Ongoing · initiated 2025-10-20

Subpotent Drug

ANTHONY TRINH, 123Herbals LLC

US Class I Ongoing · initiated 2025-10-20

Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.

Aero Healthcare

US Class II Ongoing · initiated 2025-10-17

Labeling: Label Mix-up. This issue affects the outer box labeling only. The box incorrectly states the ingredients Acetaminophen 500mg and Caffeine 65mg. The in…

Amerisource Health Services LLC

US Class II Ongoing · initiated 2025-10-16

Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable …

Amerisource Health Services LLC

US Class II Ongoing · initiated 2025-10-16

Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable …

Amerisource Health Services LLC

US Class II Ongoing · initiated 2025-10-16

Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable …

Isologic Innovative Radiopharmaceuticals Products

Canada Type III Ongoing · initiated 2025-10-16

Labelling. Verify if your product is affected.Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns…

ProRx LLC

US Class II Ongoing · initiated 2025-10-15

Lack of Assurance of Sterility

ProRx LLC

US Class II Ongoing · initiated 2025-10-15

Lack of Assurance of Sterility

ProRx LLC

US Class II Ongoing · initiated 2025-10-15

Lack of Assurance of Sterility

ProRx LLC

US Class II Ongoing · initiated 2025-10-15

Lack of Assurance of Sterility